BioStem Technologies Q1 Earnings Call Highlights Strategic Shift and Financial Performance
BioStem Technologies reported first-quarter revenue of $6.1 million, exceeding its prior guidance but declining sequentially from the previous quarter's $10.1 million. The company shifted focus to hospital sales following a late-January acquisition that added new products, customers, and GPO contracts.
Topics: acquisition impact biotech hospital market shift revenue guidance